New: March 21, 2023. The NIH sent a response to the Xtandi petition, rejecting the request to use the governments’ rights to lower the price of the prostate cancer treatment. New: March 23, 2023. The petitioners filed an appeal to… Continue Reading
Draft This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors. Timeline of privileged regarding the commercialization and use of knowledge Timeline collection: Part 1: before 1980,… Continue Reading
KEI is sending this letter to the Administration today, regarding measures we would like to see undertaken to make the humanitarian exceptions to sanctions work better. This is a neglected area of policy failure, although there is evidence that the Biden administration… Continue Reading
November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading
(For more resources, please see our page on molnupiravir.) The Medicines Patent Pool (MPP) and Merck Sharp & Dohme (“MSD” or “Merck”) have announced a voluntary license for the generic manufacture and sale of molnupiravir. A joint press release from… Continue Reading
(For more resources, please see our page on molnupiravir.) According to Brook Baker, these are the countries included in the Merck voluntary license to generic suppliers Afghanistan, Algeria, Angola, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon,… Continue Reading
(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
(For more resources, please see our page on molnupiravir.) Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug… Continue Reading
The US Federal Register has published a final rule for the “Concrete Masonry Products Research, Education, and Promotion Order.” (Link). The rule is being issued pursuant to Public Law 115-254, the FAA Reauthorization Act of 2018, which is described as… Continue Reading
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder, with an estimated incidence of between one and two cases per 10,000 births worldwide. The most severe form of the disease – SMA Type I – previously had close to 95%… Continue Reading